<DOC>
	<DOCNO>NCT00903734</DOCNO>
	<brief_summary>The goal screen portion clinical research study learn eligible take part clinical research study use Tarceva ( erlotinib hydrochloride ) either Erbitux ( cetuximab ) , Velcade ( bortezomib ) , Sprycel ( dasatinib ) . If result screen portion clinical research study show eligible take part one study describe , study drug assign take depend result biomarker analysis perform part screen test describe . Biomarkers chemical `` marker '' blood/tissue may relate body might react study drug .</brief_summary>
	<brief_title>An Umbrella , Modular Study Based Epidermal Growth Factor Receptor ( EGFR ) Mutation Status</brief_title>
	<detailed_description>Drug Administration Study visit Erlotinib hydrochloride : If take Erlotinib hydrochloride study , take Erlotinib hydrochloride mouth daily least 1 hour eat 2 hour eat . You study visit month . If continue study longer 2 cycle , study visit may become less frequent . At visit , follow test procedure perform : - Your performance status record . - You ask list drug may take , include over-the-counter drug . - You ask symptom may . - You physical exam , include measurement vital sign . - Blood ( 2 teaspoon ) collect routine test After first 8 week study , CT MRI scan check status disease . You CT MRI scan every 8 12 week . You may continue take Erlotinib hydrochloride long benefit . You take study disease get bad intolerable side effect occur . If disease get bad , study doctor may assign 1 3 study . The study doctor discus detail . Length Study : Your participation screen study screen test procedure describe complete . This investigational study . Up 102 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Patients pathologically confirm advanced metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces CR rate least 10 % improve survival least three month . 2 . Patients must tumor tissue available , either archival specimen , recent biopsy , analyze EGFR mutation . Patients must sign consent umbrella protocol prior test EGFR mutation . Patients eligible EGFRsensitive mutation , OR EGFRresistant mutation , OR EGFR mutation , benefit EGFR inhibitor therapy ( include either &gt; /= 4 month stable disease [ SD ] OR &gt; /= partial response [ PR ] ) . 3 . Measurable nonmeasurable disease . 4 . Patients must &gt; /= 6 wks beyond treatment nitrosourea mitomycinC , &gt; /= 4 wks beyond chemotherapy external beam radiation therapy ( XRT ) , must recover &lt; /= Grade 1 toxicity treatmentlimiting toxicity result prior therapy . ( Exception : patient may receive palliative low dose XRT one week treatment provide give targeted lesion ) . 5 . ( continue ) Also , patient receive nonchemotherapeutic biological agent need wait least 5 halflives 4 wks , whichever short , last day treatment . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) 7 . Patients must normal organ marrow function define : absolute neutrophil count &gt; /=1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; /= 2 X upper limit normal ( ULN ) ; total bilirubin &lt; /= 2.0 ; ALT ( SGPT ) &lt; /= 3 X ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; ALT ( SGPT ) &lt; /= 5 X ULN . 8 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 9 . Ability understand willingness sign write informed consent document . 1 . Patients uncontrolled concurrent illness , include limited : ongoing active infection ; alter mental status psychiatric illness/social situation would limit compliance study requirement and/or obscure study result . 2 . Uncontrolled systemic vascular hypertension ( systolic blood pressure &gt; 140 mm Hg , diastolic blood pressure &gt; 90 mm Hg medication ) . 3 . Patients clinically significant cardiovascular disease : history CVA within 6 month , myocardial infarction unstable angina within 6 month , unstable angina pectoris . 4 . Patients colorectal carcinoma tumor demonstrate Kirsten rat sarcoma ( KRAS ) mutation . 5 . Pregnant lactate woman 6 . Patients history bone marrow transplant within previous two year 7 . Patients know hypersensitivity component drug product . 8 . Patients treatment arm consist erlotinib dasatinib take drug potent inhibitor inducer CYP34A 9 . Patients unable swallow oral medication preexist gastrointestinal disorder might interfere proper absorption oral drug . 10 . Patients major surgery within 30 day prior enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Histology-independent</keyword>
	<keyword>EGFR Mutation</keyword>
	<keyword>EGFR inhibitor-sensitive mutation</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dasatinib</keyword>
</DOC>